With ubituximab, a high percentage of patients maintained no signs of disease activity.

Published Date: 01 Mar 2023

After receiving ublituximab treatment, the majority of patients with relapsing multiple sclerosis showed that they could achieve and maintain no evidence of disease activity.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Finding a clue to the origin of treatment-resistant leukemia in kids

2.

Survivors of childhood brain cancer are more likely to be held back in school

3.

TCL1A Protein Identified as Predictor of Blinatumomab Response in Relapsed B-ALL

4.

Adding Daratumumab to VRd Boosts MRD Negativity in Transplant-Ineligible Myeloma

5.

Utilizing cerium/lanthanum-134 to improve cancer detection and treatment.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot